Updates

Announcements

INTERIM RESULTS ANNOUNCEMENT for the six months ended 30 June 2014

Oct 2, 2014

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its interim results for the six months ended 30 June 2014. KEY HIGHLIGHTS • LupuzorTM – Announced separately today – Phase III activities of lead compound Lupuzor™ will soon commence: Following advanced discussions and after completing detailed due diligence…
Lupuzor™ Gears Up To Start Pivotal Phase III trials

Oct 2, 2014

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is delighted to announce that Phase III activities of its lead compound Lupuzor™ will soon commence. Following advanced discussions and after completing detailed due diligence with a potential partner, ImmuPharma has started the preparatory steps for Lupuzor’s™ pivotal phase III clinical…
ANNUAL GENERAL MEETING: 2014

Jun 27, 2014

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, held its AGM earlier today and is pleased to announce that all resolutions were duly passed. A summary of proxy votes is shown in the table below. Please also refer to the ‘Notice of Meeting’ in the Report & Accounts –…
ImmuPharma to access pioneering research in the Bordeaux region of France

Jun 27, 2014

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is delighted to provide further details on its activities in the Bordeaux region of France, working closely with one of its key collaborators at the CNRS*, ImmuPharma’s longstanding research partner, accessing novel drug research in the area of peptides. One key…
New Nucant Patents. New Optically Pure Compounds for Improved Therapeutic Efficiency

Jun 16, 2014

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is delighted to announce that the US Patent and Trademark Office has granted a notice of allowance for an “optically pure” version of ImmuPharma’s Nucant family. A similar grant has been obtained from the EU, Japanese and Australian patent offices. The…
PRELIMINARY RESULTS 2013: a year of substantial progress for the year ended 31 December 2013

Jun 9, 2014

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its preliminary audited results for the year ended 31 December 2013. Key Highlights: LupuzorTM Discussions continue with potential partners in parallel to discussions with Contract Research Organisations and alternative financing organisations for LupuzorTM’s pivotal Phase III programme…
Annual Report and Accounts Notice of Annual General Meeting: 27 June 2014

May 23, 2014

ImmuPharma PLC (AIM:IMM) (the “Company”) the specialist drug discovery and development company, confirms that the Annual Report and Accounts for the year ended 31 December 2013 will be posted to shareholders today. The Annual Report is available, in electronic form, for download on the Company’s website www.immupharma.co.uk. The Company’s Annual General Meeting will be held…
Dr. Sylviane Muller – Presentation Abstract from 2014 European Lupus Conference

May 6, 2014

ImmuPharma PLC (LSE: IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, provides a summary of the presentation given by Dr. Slyviane Muller at the European Lupus Conference which recently took place in Athens, Greece. The “European Lupus Meeting” is a major forum for all people interested in the disease: with approximately…
Dr. Slyviane Muller, founder of Lupuzor, presents at Osaka University, Japan

Apr 23, 2014

ImmuPharma PLC (LSE: IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce that Dr. Sylviane Muller was recently invited by the Immunology Frontier Research Center of Osaka University, an internationally renowned research center in the field of immunology, to hold a seminar on the approach of Lupuzor for…
ImmuPharma Sponsors the 2014 European Lupus Conference

Apr 11, 2014

ImmuPharma PLC (LSE: IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to confirm that it is sponsoring the forthcoming European Lupus Conference which takes place in Athens, Greece from April 23 – 26, 2014. The “European Lupus Meetings” is a major forum for all people interested in the disease:…
UPDATE: Cancer Programme IPP-204106

Aug 13, 2013

ImmuPharma plc (LSE:IMM) (“Immupharma” or the “Company” or the “Group”), the specialist drug discovery and development company is pleased to provide an update on its lead cancer programme IPP-204106. As announced in September last year the Company commenced dosing in cancer patients with the next generation of the “polyplexed Nucant” (See notes to editors). Three…
FDA Grants ImmuPharma ammended SPA for Lupuzor Phase III; Company Progresses Development Activities

Aug 12, 2013

ImmuPharma plc (LSE:IMM) (“ImmuPharma” or the “Company” or the “Group”), the specialist drug discovery and development company, is delighted to announce that following its discussions with the FDA (the US Food & Drug Administration), it has been granted an updated SPA (Special Protocol Assessment) for Lupuzor. Under the new SPA, the necessary number of patients…
Appointment of Scientific Advisory Board

Jul 8, 2013

ImmuPharma plc (LSE:IMM) (“ImmuPharma” or the “Company” or the “Group”), the specialist drug discovery and development company, is delighted to announce that it has appointed some of the world’s most eminent physicians to provide scientific advice and support for Lupuzor’s pivotal phase III programme. The Five Scientific Adisory Board members are: Dr. Daniel J. Wallace,…
ImmuPharma secures £50M financing facility for Lupuzor Phase III

May 21, 2013

Facility Underwritten by Henderson Global’s Subsidary Darwin Strategic ImmuPharma plc (LSE:IMM) (“ImmuPharma” or the “Company” or the “Group”), the specialist drug discovery and development company, is pleased to announce that it has secured a £50 million, five year Equity Financing Facility (“EFF”) with Darwin Strategic Limited (“Darwin”), a majority owned subsidiary of Henderson Global Investors’…
Immupharma gets Lupuzor research boost

Apr 8, 2013

Immupharma’s (LON:IMM) new lupus treatment Lupuzor has the potential to offer substantial benefits to patients compared with current market leader Benlysta, new research has suggested. A survey of US and European rheumatologists carried out by Decision Research indicated emerging therapies such as Lupuzor had the potential to improve on IV belimumab (Human Genome Sciences/GlaxoSmithKline’s Benlysta)…
ImmuPharma Commences Trading on the Stuttgart Stock Exchange

Feb 28, 2013

ImmuPharma PLC (LSE: IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announces that it has been informed by Baader Bank AG that its shares are now being traded on the third segment of the Stuttgart Stock Exchange. Baader Bank AG has experience and expertise for trading in German…
CNRS Confirms Lupuzor’sTM Effectiveness

Jan 28, 2013

ImmuPharma PLC (LSE: IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce that its key scientific collaboration partner and the inventor of ImmuPharma’s lead compound, LupuzorTM has issued a press release confirming the effectiveness of the LupuzorTM peptide P140. LupuzorTM is ImmuPharma’s lead compound and potential blockbuster drug…
ImmuPharma presents Lupuzor’sTM Phase IIb data at leading medical congress, the 2012 American College of Rheumatology Meeting, Washington, D.C.

Nov 20, 2012

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to today outline the key abstract information presented on Wednesday 14 November at the 2012 Annual American College of Rheumatology (“ACR”) Meeting which was held this week. The ACR Annual Scientific Meeting is the premier worldwide scientific meeting devoted…
ImmuPharma to Present Lupuzor Phase IIb Abstract / Clinical Paper at 2012 Annual ACR Meeting, Washington, D.C.

Nov 15, 2012

ImmuPharma PLC (LSE: IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to confirm that it will be presenting at the 2012 Annual American College of Rheumatology (“ACR”) Meeting which is being held between 11 – 14 of November. ImmuPharma will be presenting on Wednesday 14 November 2012. The ACR…
Cancer Programme IPP-204106 progresses into further clinical trials First cancer patients in new trial begin dosing

Oct 8, 2012

ImmuPharma plc (LSE:IMM) (“Immupharma” or the “Company” or the “Group”), the specialist drug discovery and development company, is pleased to announce that its cancer programme IPP-204106 has begun further clinical trials with the next generation of “polyplexed Nucant”. The first patients have started dosing in this new Phase I/ II clinical trial. This “polyplexed Nucant”…
ImmuPharma to present at Rodman and Renshaw Annual Global Investment Conference, New York – Tuesday 11 September 2012

Sep 7, 2012

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to confirm that it will be presenting at the Rodman and Renshaw Annual Global Investment Conference on Tuesday 11 September 2012 at the Waldorf Astoria in New York City. Tracy Weimar, Vice President, Operations and Finance will present an…

2026 (15)

2025 (24)

2024 (19)

2023 (25)

2022 (27)

2021 (21)

2020 (40)

2019 (19)

2018 (22)

2017 (17)

2016 (25)

2015 (17)

2014 (12)

A prodrug is a pharmacologically inactive or much less active compound that is converted inside the body (usually by metabolic enzymes) into the active drug that actually produces the therapeutic effect.

Lisa Baderoon

Non-Executive Director and Head of Investor Relations

Lisa has spent over 25 years working within the City of London being involved with a diverse portfolio of clients from a variety of sectors but with a leaning towards emerging, high growth businesses advising both private and public companies on their financial and corporate strategies aligned to stakeholder and investor interests, as well as a strong acumen in media communication. During this time, she has been involved in a multitude of client transactions spanning private fund raisings, Initial Public Offerings (IPOs), secondary high profile capital raisings and mergers and acquisitions both in the UK and internationally.

Lisa had a successful career spanning 20 years as a Partner at Buchanan Communications, one of the leading City financial public relations agencies. As one of the youngest Board members, she was involved in the successful five-year earnout, as part of Buchanan being acquired by the FTSE 100 rated WPP Plc in 1997.

Lisa founded Just B Communications Ltd in 2012 with the key objective of working with a more select number of clients and providing a greater degree of bespoke advisory services thus becoming more integral to the day to day corporate and strategic development for these businesses. She has successfully advised a number of public and private companies, at Board level, on corporate strategy, stakeholder and investor communications, capital raisings, dual listings, licensing and M&A. Media profiling, where required, has also played an important role in advisory activities.

Lisa was appointed Head of Investor Relations at ImmuPharma in 2012 and most recently appointed as a Non-Executive Director in July 2021.

Ketan Patel

Independent Non-Executive Director

Ketan is an experienced investment professional who brings extensive expertise in financial markets, with a particular focus on the UK healthcare and life science sectors. He has been a long-term investor in UK markets, working as both an analyst and Fund Manager, managing institutional, retail, and charity mandates. Ketan began his career at JP Morgan before moving to Insight Investment, where he served as a global Pharmaceutical and Healthcare analyst. He then spent over 20 years at EdenTree Investment Management, where he was responsible for UK equity and global equity income strategies, consistently delivering upper-quartile performance.

Ketan combines rigorous fundamental analysis with risk-focused investment strategies. He is also a published thought leader on sustainability and investment themes. Ketan is a CFA Charterholder and holds an MSc in Economic History from the London School of Economics, an MSc in Geography from King’s College London, and a BA (Hons) in History and Geography from Queen Mary University, London.

Dr Laurence Reilly MD, LLM

Senior Independent Non-Executive Director

Dr Laurence Reilly has been appointed as Senior independent Non-Executive Director and Chair of the Audit Committee. Dr Reilly brings extensive experience in managing late-stage clinical programs through to approval, in addition to commercial and business development experience.

He is currently Vice President of Research & Investments, working with Royalty Pharma, a New York based life science investment company focussing on acquisition of biopharmaceutical royalties and funding of innovation across the biopharmaceutical industry.

Through his consulting practice (Acumen Life Science Investment Consulting) Dr Reilly has provided strategic consulting and due-diligence services to biotech companies, life science venture capital and private equity clients. He also served as Chief Medical Officer for Cellectar Biosciences, New Jersey, a late-stage oncology biotech company. Prior to founding his consulting practice, Dr Reilly served as Chief Scientific Officer and Vice President at Avillion, a drug development company focused on the co-development and financing of drug candidates, where he was responsible for clinical and strategic oversight of co-development programs and partnering with both large pharma and biotech, including Pfizer, Merck KGaA and AstraZeneca. Dr. Reilly previously served as a Clinician – Clinical Development & Medical Oversight at Pfizer and at Lundbeck as Medical & Scientific Advisor.

Dr Reilly earned his medical degree from the University of Liverpool Medical School, U.K., and practiced as Neurosurgery Resident at Queen Elizabeth University Hospital in Birmingham. Dr Reilly also holds a Masters Degree in Law from De Montfort University, U.K.

Dr Tim Franklin PhD, MBA

Chief Operating Officer

Tim has 38 years’ experience in the biopharmaceutical industry. He worked in clinical research, sales & marketing, and global strategic marketing for Warner Lambert, Wellcome and SmithKline Beecham. He later moved to the capital markets where he became a top-ranked pharmaceuticals analyst at Dresdner Kleinwort investment bank. He applied his experience to stock selection at hedge funds and advised several small biotechnology companies on corporate and commercial strategy and access to capital. He holds a BSc in Medicinal Chemistry and a PhD in Pharmacology from Loughborough University and an MBA from Warwick Business School.

Dr Laura Mauran-Ambrosino Ph.D.

Head of R&D

Born in Montpellier, France, Dr. Mauran-Ambrosino obtained her PhD in Chemistry from the Université de Bordeaux as a CIFRE fellow under the co-supervision of Dr. Goudreau. She then conducted postdoctoral research in cell biology at the Centre Hospitalier Universitaire (CHU) Pellegrin in Bordeaux.

In 2018, she joined Ureka, where she established both the Biology and Analytical Chemistry departments. In 2021, she became Chief Scientific Officer of Ureka Pharma. Since 2025, Dr. Mauran-Ambrosino has served as Head of R&D of the ImmuPharma Group.

Dr. Mauran-Ambrosino was a key contributor to the development of several programs, including BioAMB, BioCIN, the P140 companion diagnostic, and Kapiglucagon.

Ashley Clarke ACA

Chief Financial Officer & Company Secretary

Ashley brings over a decade of experience in the financial sector. She began her career at a Big Four accounting firm and later advanced her professional expertise by earning her ACA qualification with a respected local firm.

Her professional journey is rooted in auditing, where she developed expertise working with a diverse portfolio of audit and non-audit clients across various industries. Ashley’s experience spans from supporting SMEs to managing large international group consolidations, giving her a comprehensive understanding of financial management across different business scales.

Ashley has been closely involved with the company’s accounts for several years via outsourced accountants, providing her with deep familiarity with its operations. Now, as Group CFO and Company Secretary, she is poised to leverage her extensive knowledge to drive strategic financial growth and ensure robust fiscal management.

Dr Sébastien R. Goudreau Ph.D.

Chief Scientific Officer

Born in Sherbrooke, Québec, Canada, Dr. Sébastien Goudreau obtained his PhD in Chemistry from the Université de Montréal as an NSERC fellow before conducting postdoctoral research at ETH Zürich as an FRQNT fellow. He later returned to Canada, where he co-founded FindMolecule Inc. and worked in the pharmaceutical industry.

Dr. Goudreau joined ImmuPharma in 2014 as Research Director and established the Ureka research laboratories in Bordeaux. Following the merger of ELRO and Ureka in 2019, he became Chief Scientific Officer of Ureka Pharma. In 2021, he was appointed Chief Executive Officer of ImmuPharma Biotech, and since 2025 he has served as Chief Scientific Officer of the ImmuPharma Group.

Dr. Goudreau and his team are credited with the discovery and development of several innovative programs, including BioAMB, BioCIN, the P140 companion diagnostic, and Kapiglucagon.

Tim McCarthy FCCA, MBA

Chief Executive Officer

Tim has 45 years’ international senior level business experience in high growth biotech, healthcare and technology companies. Tim was formerly Chairman of Incanthera plc and 4basebio plc and CEO and CFO of a number of UK public listed and private companies including, Alizyme plc and Peptide Therapeutics Group plc, and has a core understanding of AIM and its regulatory processes. Co-founding a number of healthcare and biotechnology companies, he has helped raise substantial amounts of equity capital and also advised and worked at Board level for a diverse range of companies internationally, in areas such as business strategy, mergers & acquisitions, due diligence and licensing.

INTERIM RESULTS ANNOUNCEMENT for the six months ended 30 June 2014

Lupuzor™ Gears Up To Start Pivotal Phase III trials

ANNUAL GENERAL MEETING: 2014

ImmuPharma to access pioneering research in the Bordeaux region of France

New Nucant Patents. New Optically Pure Compounds for Improved Therapeutic Efficiency

PRELIMINARY RESULTS 2013: a year of substantial progress for the year ended 31 December 2013

Annual Report and Accounts Notice of Annual General Meeting: 27 June 2014

Dr. Sylviane Muller – Presentation Abstract from 2014 European Lupus Conference

Dr. Slyviane Muller, founder of Lupuzor, presents at Osaka University, Japan

ImmuPharma Sponsors the 2014 European Lupus Conference

UPDATE: Cancer Programme IPP-204106

FDA Grants ImmuPharma ammended SPA for Lupuzor Phase III; Company Progresses Development Activities

Appointment of Scientific Advisory Board

ImmuPharma secures £50M financing facility for Lupuzor Phase III

Immupharma gets Lupuzor research boost

ImmuPharma Commences Trading on the Stuttgart Stock Exchange

CNRS Confirms Lupuzor’sTM Effectiveness

ImmuPharma presents Lupuzor’sTM Phase IIb data at leading medical congress, the 2012 American College of Rheumatology Meeting, Washington, D.C.

ImmuPharma to Present Lupuzor Phase IIb Abstract / Clinical Paper at 2012 Annual ACR Meeting, Washington, D.C.

Cancer Programme IPP-204106 progresses into further clinical trials First cancer patients in new trial begin dosing

ImmuPharma to present at Rodman and Renshaw Annual Global Investment Conference, New York – Tuesday 11 September 2012